Correlation of Quantitative Myasthenia Gravis and Myasthenia Gravis Activities of Daily Living scales in the MGTX study

被引:19
|
作者
McPherson, Tarrant [1 ]
Aban, Inmaculada [1 ]
Duda, Petra W. [2 ]
Farzaneh-Far, Ramin [2 ]
Wolfe, Gil, I [3 ]
Kaminski, Henry J. [4 ]
Cutter, Gary [1 ]
Lee, Ikjae [5 ]
机构
[1] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35233 USA
[2] Ra Pharmaceut, Cambridge, MA USA
[3] Univ Buffalo State Univ New York, Jacobs Sch Med & Biomed Sci, Dept Neurol, Buffalo, NY USA
[4] George Washington Univ, Sch Med & Hlth Sci, Dept Neurol, Washington, DC 20052 USA
[5] Univ Alabama Birmingham, Dept Neurol, 200 Sparks Ctr,1720 7th Ave South, Birmingham, AL 35233 USA
关键词
MG-ADL; MGTX; myasthenia gravis; outcome measure; QMG; trial design; MYCOPHENOLATE-MOFETIL; RANDOMIZED-TRIAL; ECULIZUMAB;
D O I
10.1002/mus.26910
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction Quantitative Myasthenia Gravis (QMG) and Myasthenia Gravis Activities of Daily Living (MG-ADL) scales were compared using the data from the Thymectomy Trial in Non-Thymomatous Myasthenia Gravis Patients Receiving Prednisone Therapy (MGTX) study. Methods Correlation between QMG and MG-ADL raw and change-from-baseline scores was calculated every 3 months for 60 months based on treatment groups and minimal manifestation status (MMS). Results QMG and MG-ADL change-from-baseline scores correlated significantly, with increasing strength of correlation over time, in both treatment groups. QMG and MG-ADL raw scores correlated significantly in both treatment groups, with increasing correlation only in the prednisone-alone group. Correlation between raw scores was weaker in patients who were in MMS, demonstrating a "floor effect" on the MG-ADL scale. Raw QMG scores could be modeled assuming a normal distribution, whereas raw MG-ADL scores could not be modeled this way. Discussion The floor effect and skewed distribution of the MG-ADL measure should be taken into account in the design of myasthenia gravis clinical trials.
引用
收藏
页码:261 / 265
页数:5
相关论文
共 50 条
  • [41] Myasthenia Gravis
    Aarli, Johan A.
    Gilhus, Nils Erik
    Lisak, Robert P.
    Mantegazza, Renato
    Suzuki, Shigeaki
    AUTOIMMUNE DISEASES, 2011, 2011
  • [42] Myasthenia gravis
    Schodrowski J.
    Seipelt M.
    Adibi-Sedeh I.
    Eienbröker C.
    Tackenberg B.
    Spektrum der Augenheilkunde, 2017, 31 (3-4) : 159 - 171
  • [44] Myasthenia gravis
    Chaplin, S
    BRITISH MEDICAL JOURNAL, 1943, 1943 : 21 - 22
  • [45] Myasthenia gravis
    Vincent, A
    Palace, J
    Hilton-Jones, D
    LANCET, 2001, 357 (9274): : 2122 - 2128
  • [46] Myasthenia gravis
    Keesey, J
    ARCHIVES OF NEUROLOGY, 1998, 55 (05) : 745 - 746
  • [47] Myasthenia Gravis
    Indraratna, Praveen
    Matar, Walid
    NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (13):
  • [48] MYASTHENIA GRAVIS
    STRAUSS, AJL
    BRITISH MEDICAL JOURNAL, 1963, (532): : 57 - +
  • [49] MYASTHENIA GRAVIS
    GILBERT, PG
    GOLDMAN, J
    JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1968, 206 (11): : 2525 - &
  • [50] Myasthenia gravis
    Hamacher, Allyson
    JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2025, 38 (02): : 45 - 46